Asiaticoside and endothelial senescence in diabetic retinopathy: mouse and cell study
In a diabetic mouse model and high-glucose human microvascular endothelial cells, asiaticoside reduced signs of cellular senescence and retinal vascular leakage; the abstract links these effects to CCND1 and the PI3K-AKT-mTOR pathway. [1]
Automatic summary · not editorially reviewed
The key findings
Diabetic C57BL/6J mice were treated with asiaticoside, and human microvascular endothelial cells exposed to 35 mM glucose were also treated with it. [1]
Asiaticoside lowered the visual contrast threshold by about 18% and reduced retinal vascular leakage in diabetic mice. [1]
The PI3K agonist 740-YP completely reversed the beneficial effects of asiaticoside in the cell experiments. [1]
The source at a glance
- Study type / format
- Preclinical animal and cell study (abstract)
- Population / context
- Streptozotocin-induced diabetic C57BL/6J mice and human microvascular endothelial cells exposed to high glucose
- Summary based on
- Study abstract
- Original publication
- August 1, 2026
Diabetic mice and high-glucose endothelial cells
The study used C57BL/6J mice made diabetic with streptozotocin injections and then treated with asiaticoside. In parallel, human microvascular endothelial cells were exposed to high glucose (35 mM) and treated with asiaticoside. To probe mechanisms, the cells were also treated with a mitophagy inhibitor (3-MA), a mitophagy agonist (CCCP) and a PI3K agonist (740-YP), and CCND1 was reduced with small interfering RNA. Outcomes included retinal senescence markers, visual contrast sensitivity, retinal vascular leakage, cell viability, senescence, migration, apoptosis, mitophagy and mitochondrial measures.
Supporting source [1]
Lower contrast threshold and less vascular leakage in mice
According to the abstract, asiaticoside treatment lowered the visual contrast threshold by about 18% and reduced retinal vascular leakage in the diabetic mice. In the cell experiments, asiaticoside lessened high-glucose-induced endothelial senescence and cellular and mitochondrial dysfunction, reduced reactive oxygen species production and induced mitophagy. Bioinformatics analysis identified CCND1 as one of the key senescence-related genes upregulated in diabetic retinopathy, and asiaticoside significantly inhibited its overexpression. Reducing CCND1 reproduced the protective effects, enhancing mitophagy and suppressing senescence features.
Supporting source [1]
PI3K agonist reversed asiaticoside effects in cells
The abstract reports that asiaticoside treatment or CCND1 reduction inhibited high-glucose-induced activation of the PI3K-AKT-mTOR signaling pathway, and that the PI3K agonist 740-YP completely reversed the beneficial effects of asiaticoside. The authors describe this as the first exploration of CCND1's pathological role in diabetic retinopathy beyond its classical cell-cycle function and propose it as a therapeutic target. These are preclinical mouse and cell findings; the abstract does not report human trials, and the proposed treatment strategy has not been shown to work in people.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Findings come from a streptozotocin mouse model and high-glucose human endothelial cells, not from studies in people. The abstract does not report sample sizes, follow-up duration or statistical uncertainty, and the proposed therapeutic strategy remains untested in humans.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Chen Z, Luo Y, Lou X, Chen S, Qian Y, Yang X, Yu Y. · europepmc.org · August 1, 2026